Skip to main content
Have a personal or library account? Click to login
Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib Cover

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib

Radiology and Oncology
Volume 52 (2018): Issue 2 (June 2018)
By: Ana Ursula Gavric,  Janja Ocvirk and  Polona Jaki Mekjavic  
Open Access
|Jan 2018
Authors

Authors

Ana Ursula Gavric

Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

Janja Ocvirk

Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Polona Jaki Mekjavic

polona.jaki@guest.arnes.si

Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
DOI: https://doi.org/10.2478/raon-2018-0002 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 213 - 219
Submitted on: Oct 4, 2017
Accepted on: Nov 20, 2017
Published on: Jan 24, 2018
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
metastatic malignant melanoma,
eye,
MEKAR,
MEK inhibitor
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2018 Ana Ursula Gavric, Janja Ocvirk, Polona Jaki Mekjavic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 52 (2018): Issue 2 (June 2018)
Previous article
Next article